News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GammaCan International, Inc. (GCAN.OB) Retains Investor Relations Firm ROI Group


6/27/2007 1:31:33 PM

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced it has retained investor relations firm ROI Group.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES